Agile Health Revenue and Competitors
Estimated Revenue & Valuation
- Agile Health's estimated annual revenue is currently $8.4M per year.
- Agile Health's estimated revenue per employee is $216,000
Employee Data
- Agile Health has 39 Employees.
- Agile Health grew their employee count by 44% last year.
Agile Health Competitors & Alternatives
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $18M | 95 | 10% | N/A | N/A |
#2 | $4.9M | 34 | 31% | N/A | N/A |
#3 | $116.1M | 344 | 12% | N/A | N/A |
#4 | $7.3M | 44 | 2% | N/A | N/A |
#5 | $141.4M | 419 | 11% | N/A | N/A |
#6 | $544.3M | 1440 | 5% | N/A | N/A |
#7 | $4.5M | 31 | 35% | N/A | N/A |
#8 | $7.8M | 46 | 7% | N/A | N/A |
#9 | $41.9M | 141 | 15% | N/A | N/A |
#10 | $373.1M | 987 | 16% | N/A | N/A |
What Is Agile Health?
Agile Health is a digital health engagement company leveraging the power of text messaging to improve population health and achieve better healthcare outcomes through lasting behavior change. Agile's secure, proprietary platform delivers a suite of highly interactive, evidence-based programs with a substantive record of clinical validation and proven results. The Agile solution creates a personal, relevant digital experience engaging more people, more intensively, and more cost effectively.
keywords:N/AN/A
Total Funding
39
Number of Employees
$8.4M
Revenue (est)
44%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Agile Health News
Eukanuba Premium Performance Puppy Pro provides glucosamine and chondroitin sulfate with EPA to promote agile joint health. Immune Support.
The health crisis just accelerated a process that was bound to happen. In today's context, companies with increased agility operate with more...
Healthcare Breakthroughs: AGRX, NMLSF, BBI, LMLLF; BioMed Leaders Report ... Agile Therapeutics (NASDAQ: AGRX) CEO Al Altomari: Brand is...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $4M | 39 | 11% | N/A |
#2 | $3.5M | 40 | -7% | N/A |
#3 | $7.6M | 42 | 20% | N/A |
#4 | $9M | 59 | -3% | N/A |
#5 | N/A | 60 | 1100% | N/A |